Amoxicillin potassium clavulanate
ApprovedSmall molecule
Amoxicillin potassium clavulanate is one of 65 small molecule programs targeting Sinusitis. It is currently in Approved.
2
Indications
6
Total Trials
0
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
94 competitors in Sinusitis
#DrugCompanyPhaseTrials
1Ketek
SanofiApproved
Cipro
BayerApproved
Nurtec
PfizerApproved
Asmanex Hfa
PPerrigo Company
Approved
Kenalog
BBassett Healthcare
Approved
Tobrex
VViatris Specialty LLC
Approved
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Inomax
MMallinckrodt
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
Normodyne
AAlvogen Korea
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Antibiotic Prophylaxis1 trial
Functional Endoscopic Sinus Surgery1 trial
Bacteremia1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]
- [4]
Details